Clinical Trial Update: Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART [Phase 1]

View source ↗

Summary

A Phase 1 trial assessed the safety and immunogenicity of the MVA.HIVconsv HIV vaccine in HIV-1 seropositive adults on HAART, but the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MVA.HIVconsv

Snippet

Sponsor: University of Oxford | Conditions: HIV-1 | Phase 1 | Status: TERMINATED